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Type 2 diabetes mellitus (T2DM) is a widespread metabolic disorder that has reached epidemic 
proportions globally, and is now considered to be one of the main threats to human health. The 
currently available treatment options in T2DM suffer from inadequate efficacy and durability, as well 
as liabilities, including hypoglycemia, weight gain, edema and gastrointestinal intolerance. Since the 
efficacy and patient compliance of existing treatments are in many cases unsatisfactory, there is a 
pronounced need for novel targets, which could complement current treatment. 
Evidence accumulated during the last two decades indicates that excessive caloric intake and obesity 
lead to a chronic low-grade inflammation in metabolic tissues, and increased inflammation may be 
directly involved in the pathogenesis of T2DM. Therefore, novel pharmacological treatments 
targeting both the metabolic and inflammatory disruptions seen in T2DM are warranted. 
AMP-activated protein kinase (AMPK) is a central master switch important for regulating energy 
homeostasis at cellular as well as whole body level. Recently, evidence for a role of AMPK in 
regulation of inflammatory balance has emerged. By using AMPK agonists AICAR and metformin in 
liver cell lines, primary hepatocytes and in mouse model system in vivo, we demonstrate that AMPK 
activation in liver leads to decreased inflammatory response to the proinflammatory cytokine IL-6. 
We further show that the anti-inflammatory action of AMPK was mediated via decreased 
phosphorylation of several downstream components of the canonical IL-6 receptor signalling 
pathway. Inhibition of the IL-6 signalling cascade in liver by AMPK supports a role of this kinase as 
a crucial point of convergence of metabolic and inflammatory pathways in hepatocytes. 
Serine/threonine protein kinase 25 (STK25) is broadly expressed in mouse, rat and human tissues. 
When activated, this kinase is part of several cell processes, such as development, migration and 
apoptosis. We, for the first time, show that STK25 also has metabolic effects. By using small 
interfering RNA for Stk25 in rodent muscle cell line L6, we demonstrate that STK25 is involved in 
regulation of glucose uptake and lipid oxidation. Furthermore, mice overexpressing STK25, when 
challenged with a high-fat diet, develop reduced glucose tolerance and insulin sensitivity compared 
to wild-type siblings. Increased triglyceride deposition in liver and skeletal muscle, and adipocyte 
hypertrophy, as observed in Stk25 transgenic mice, suggest that the underlying cause of insulin 
resistance in conditions of excess dietary fuels is a shift in the metabolic balance from lipid oxidation 
toward lipid storage in peripheral tissues. Furthermore, Stk25 transgenic mice show increased 
infiltration of inflammatory cells in liver. 
Taken together, both AMPK and STK25 emerge as interesting targets for future treatment of T2DM, 
enabling to target the dysregulation of both metabolism and inflammation seen in connection with 
this disease. 
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